Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).

Employees

118

Sector

Biotechnology & Medical Research

Calendar

Feb. 04 - Western Society of Allergy Asthma and Immunology Scientific Meeting

More about the company

Quotes

Date	Price	Change	Volume
26-01-15	25.65 $	+0.08%	133,677
26-01-14	25.63 $	-1.42%	251,966
26-01-13	26.00 $	-0.38%	191,229
26-01-12	26.10 $	+0.81%	266,735
26-01-09	25.89 $	+3.56%	315,117

Delayed Quote Nasdaq, January 15, 2026 at 04:00 pm EST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

21.99EUR

Average target price

39.43EUR

Spread / Average Target

+79.30%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-15 pm EST			5-day change	1st Jan Change
25.65 ^USD	+0.08%		+2.60%	-7.57%

Dec. 21	Pharvaris N.V.(NasdaqGS:PHVS) added to NASDAQ Biotechnology Index	CI
Dec. 04	Pharvaris' Phase 3 Trial of Deucrictibant for HAE Attacks Confirms a Differentiated On-Demand Profile, Morgan Stanley Says	MT

Capitalization	1.43B 1.66B 1.33B 1.24B 2.3B 150B 2.47B 15.3B 6.02B 71.64B 6.22B 6.09B 263B	P/E ratio 2025 *	-7.75x	P/E ratio 2026 *	-7.94x
Enterprise value	1.1B 1.27B 1.02B 952M 1.77B 115B 1.9B 11.75B 4.63B 55.05B 4.78B 4.68B 202B	EV / Sales 2025 *	-	EV / Sales 2026 *	-
Free-Float	60.48%	Yield 2025 *	-	Yield 2026 *	-

Dec. 21	Pharvaris N.V.(NasdaqGS:PHVS) added to NASDAQ Biotechnology Index	CI
Dec. 04	Pharvaris' Phase 3 Trial of Deucrictibant for HAE Attacks Confirms a Differentiated On-Demand Profile, Morgan Stanley Says	MT
Dec. 04	Morgan Stanley Raises Price Target on Pharvaris to $41 From $37, Keeps Overweight Rating	MT
Dec. 03	Pharvaris N.V. - Special Call
Dec. 03	Sector Update: Health Care Stocks Advance Premarket Wednesday	MT
Dec. 03	US Equity Futures Rise as Wall Street Digests Labor Market Data	MT
Dec. 03	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Amid Economic Data Releases	MT
Dec. 03	Pharvaris announces positive topline data from Rapide-3 pivotal study	RE
Dec. 03	Top Premarket Gainers	MT
Dec. 03	Pharvaris Says Phase 3 Deucrictibant Trial Meets Endpoints in Hereditary Angioedema	MT
Dec. 03	Pharvaris Announces Positive Topline Data from Rapide-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of Hae Attacks	CI
Nov. 13	Wedbush Raises Price Target on Pharvaris to $30 From $27, Keeps Outperform Rating	MT
Nov. 12	Pharvaris N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Dec. 04	Pharvaris' Phase 3 Trial of Deucrictibant for HAE Attacks Confirms a Differentiated On-Demand Profile, Morgan Stanley Says	MT
Dec. 04	Morgan Stanley Raises Price Target on Pharvaris to $41 From $37, Keeps Overweight Rating	MT
Nov. 13	Wedbush Raises Price Target on Pharvaris to $30 From $27, Keeps Outperform Rating	MT
25-10-15	HC Wainwright Initiates Coverage on Pharvaris N.V With Buy Rating, $60 Price Target	MT
25-08-15	BofA Securities Adjusts Price Target on Pharvaris to $16 From $14, Maintains Underperform Rating	MT

Pharvaris N.V. Stock

Equities

PHVS

NL00150005Y4

Biotechnology & Medical Research

Valuation: Pharvaris N.V.

Chart: Pharvaris N.V.

Latest news: Pharvaris N.V.

Last Transcript: Pharvaris N.V.

Analysts' recommendations: Pharvaris N.V.

Press Releases: Pharvaris N.V.

News in other languages: Pharvaris N.V.

Quotes and Performance

Course Extremes

Managers and Directors: Pharvaris N.V.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Jan. 12	Pharvaris Outlines 2026 Strategic Priorities	GL
Dec. 03	Pharvaris N : RAPIDe 3 Public Slides FINAL	PU
Dec. 03	Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks	GL
Dec. 01	Pharvaris N : Gurugama BSI CIPN25 CH 1 OLE Poster 20Nov2025 FINAL UPLOAD NO QR	PU
Dec. 01	Pharvaris N : Kiani Alikhan et al (BSI CIPN) RE 2 24Nov2025 FINAL NO QR	PU

25-10-03	Pharvaris N : (DAK 2025) RAPIDe 2 ePoster FINAL 30Sep2025 UPLOAD NO QR
25-10-03	Pharvaris N : (DAK 2025) CHAPTER 1 OLE ePoster FINAL 30Sep2025 UPLOAD NO QR
25-10-03	Pharvaris N : Guilarte (SEAIC 25 Grenada)Durability 02Oct2025 ES FINAL NO QR
25-10-02	Pharvaris N : Caballero et al (SEAIC Granada25) AAE Interviews Poster 10Sep2025 FINAL UPLOAD SPANISH NO QR
25-08-07	Pharvaris N : Zwiener et al (AAAeIC25) CHAPTER 3 SD Oral Poster 05Aug2025 NoQRcode

1 day	+0.08%
1 week	+2.60%
Current month	-7.57%
1 month	+7.32%
3 months	+17.77%
6 months	+11.57%
Current year	-7.57%

1 week	24.71	27.1
1 month	23.62	28.43
Current year	23.62	28.43
1 year	11.51	29.8
3 years	6.02	33
5 years	1.77	42.86
10 years	1.77	42.86

Manager	Title	Age	Since
Anne Lesage PRN	Corporate Officer/Principal	65	2015-09-29
Berndt A. E. Modig CEO	Chief Executive Officer	67	2015-09-29
David Nassif DFI	Director of Finance/CFO	72	2024-04-14

Director	Title	Age	Since
Berndt A. E. Modig BRD	Director/Board Member	67	2015-09-29
Johannes G. C. P. Schikan BRD	Director/Board Member	68	2015-09-29
Robert Glassman BRD	Director/Board Member	64	2020-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
PHARVARIS N.V.	+0.08%	+2.60%	+54.05%	+178.80%	1.66B
LONZA GROUP AG	+1.11%	+2.66%	+4.99%	+15.10%	49.05B
IQVIA HOLDINGS INC.	-0.03%	-0.79%	+23.04%	+8.91%	41.1B
BEONE MEDICINES AG	-2.44%	+5.59%	+67.70%	+26.38%	38.37B
CELLTRION, INC.	-0.47%	-0.24%	+18.66%	+36.02%	31.59B
REVOLUTION MEDICINES, INC.	+1.69%	+14.79%	+208.48%	+350.22%	23.43B
MEDPACE HOLDINGS, INC.	+0.26%	+3.00%	+84.36%	+170.34%	17.36B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	-14.53%	-27.43%	+23,494.98%	+3,950.67%	17.39B
EUROFINS SCIENTIFIC SE	+0.64%	+5.01%	+57.25%	+12.41%	14.83B
ICON PUBLIC LIMITED COMPANY	-1.20%	-3.01%	-8.48%	-19.02%	14.11B
Average	-1.49%	-1.60%	+2,400.50%	+472.98%	24.89B
Weighted average by Cap.	-1.09%	-0.52%	+1,688.01%	+334.83%

	2025 *	2026 *
Net sales	-	-
Net income	-163M -189M -152M -141M -262M -17.06B -281M -1.74B -685M -8.16B -708M -694M -29.92B	-181M -210M -169M -157M -292M -18.99B -313M -1.94B -763M -9.08B -788M -772M -33.31B
Net Debt	-331M -384M -308M -287M -534M -34.71B -573M -3.54B -1.39B -16.59B -1.44B -1.41B -60.87B	-363M -421M -338M -315M -585M -38.06B -628M -3.89B -1.53B -18.2B -1.58B -1.55B -66.75B